BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HT-4253 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HT-4253\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07399171-731@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:HT-4253: Phase 2 readout est. (NCT07399171)
DESCRIPTION:HT-4253\, phase 2\, Alzheimer's Disease.\nStudy: Study to Evalu
 ate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APO
 E4 Carriers\nEstimated primary completion: February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ht-4253#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07399171
URL:https://assetmemo.bio/drug/ht-4253#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
